Market capitalization | $315.07m |
Enterprise Value | $64.29m |
PER (TTM) P/E ratio | 14.02 |
EV/FCF (TTM) EV/FCF | 0.48 |
EV/Sales (TTM) EV/Sales | 0.21 |
P/S ratio (TTM) P/S ratio | 1.03 |
P/B ratio (TTM) P/B ratio | 0.74 |
Sales growth (TTM) Sales growth | -35.83% |
Turnover (TTM) Turnover | $304.64m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
6 Analysts have issued a OraSure Technologies, Inc. forecast:
6 Analysts have issued a OraSure Technologies, Inc. forecast:
Mar '24 |
+/-
%
|
||
Turnover | 305 305 |
36%
36%
|
|
Gross income | 131 131 |
31%
31%
|
|
EBITDA | 35 35 |
31%
31%
|
EBIT (operating result) EBIT | 15 15 |
57%
57%
|
Net profit | 23 23 |
22%
22%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.
Head office | United States |
CEO | Carrie Manner |
Employees | 638 |
Founded | 2000 |
Website | www.orasure.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.